Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's DiseaseBy Janssen Pharmaceutica N.v., PRNE
Tuesday, November 30, 2010
BEERSE, Belgium, December 1, 2010 - Janssen Pharmaceutica N.V., (Janssen) today announced a research
agreement to collaborate with GE Healthcare to develop non-invasive or
minimally invasive diagnostic biosignatures to detect Alzheimer's disease
prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will
allow earlier diagnosis of the disease and may enable significantly earlier
intervention in Alzheimer's disease.
This collaboration will bring together Janssen's clinical, biomarker, and
informatics - expertise with the imaging and diagnostic capabilities at GE to
identify combinations of biomarkers - also known as biosignatures - that are
specific to Alzheimer's disease. In complex diseases such as Alzheimer's,
biosignatures are believed to provide greater diagnostic value than
"The underlying pathologies associated with Alzheimer's disease, such as
the formation of amyloid plaques and tau tangles in the tissues of the brain,
can precede the onset of memory loss and other clinical symptoms by decades,"
said Husseini K. Manji, M.D., Global Therapeutic Area Head, Neuroscience
Research & Development, Johnson & Johnson Pharmaceutical Research &
Development. "In establishing biosignatures of Alzheimer's disease, we will
enable non-invasive identification of disease pathologies that help support
earlier diagnosis and regular monitoring of disease progression. These in
turn may allow earlier intervention in the disease process, when there may be
more opportunity to delay or diminish clinical symptoms."
According to the Alzheimer's Association, deaths attributed to the
disease have increased by more than 46% between 2000 and 2006. Today, in the
US alone, 5.3 million people have Alzheimer's disease, and the annual cost of
the disease is $172 billion. It is the 6th leading cause of death, and its
mortality rates are expected to rise as the baby boomer population ages.[i]
In last year's World Alzheimer's Report, Alzheimer's Disease International
estimated that there are 35.6 million people living with dementia worldwide
in 2010, increasing to 65.7 million by 2030 and 115.4 million by 2050.[ii]
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our time,
including oncology (e.g. multiple myeloma and prostate cancer), immunology
(e.g. psoriasis),neuroscience (e.g. schizophrenia, dementia and pain),
infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and
cardiovascular and metabolic diseases (e.g. diabetes).
Driven by our commitment to patients, we develop sustainable, integrated
healthcare solutions by working side-by-side with healthcare stakeholders,
based on partnerships of trust and transparency.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
is a wholly owned subsidiary of Johnson & Johnson, the world's most broadly
based producer of health care products. J&JPRD is headquartered in Raritan,
N.J., and has facilities throughout Europe, the United States and Asia.
J&JPRD is leveraging drug discovery and drug development in a variety of
therapeutic areas, including CNS, Internal Medicine and Oncology, to address
unmet medical needs worldwide. More information can be found at
[i] 2010 Alzheimer's Disease Facts and Figures. Alzheimer's Association
Accessed November 9, 2010.
[ii] World Alzheimer's Report 2010. Alzheimer's Disease International
Accessed November 30, 2010.
Media Contact: Srikant Ramaswami Office: +1-609-730-2658 Cell: +1-609-647-8195 Email: Sramaswa@its.jnj.com
Srikant Ramaswami of Janssen Pharmaceutica N.V., Office: +1-609-730-2658, Cell: +1-609-647-8195, Sramaswa at its.jnj.com
Tags: Beerse, belgium, December 1, Janssen Pharmaceutica N.v., Western Europe